Clinical Audit of Denosumab Biosimilar for Aggressive GCT of Bone: A Tertiary Care Center Retrospective Analysis

Slični predmeti

• Phase III Study to Confirm Clinical Similarity of MB09, a Denosumab Biosimilar, and Prolia^® in Postmenopausal Women with Osteoporosis (SIMBA Study)
  od: Jerzy Supronik, i dr.
  Izdano: (2026-02-01)
• Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of CMAB807, a New Denosumab Biosimilar, in Healthy Chinese Subjects
  od: Hanjing Chen, i dr.
  Izdano: (2022-01-01)
• A randomized trial comparing LY01011, biosimilar candidate, with the reference product denosumab (Xgeva®) in healthy Chinese subjects
  od: Yanhua Ding, i dr.
  Izdano: (2023-10-01)
• A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of QL1206 to Denosumab Among Chinese Healthy Subjects
  od: Hong Zhang, i dr.
  Izdano: (2020-10-01)
• Clinical Audit of Denosumab Biosimilar for Aggressive GCT of Bone: A Tertiary Care Center Retrospective Analysis
  od: Rajesh B. Singh, i dr.
  Izdano: (2025-10-01)